Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer ...

HARTFORD, Conn. (WTNH) — Radiation therapy plays a crucial role in treating breast cancer, but it can also bring challenges that last long after treatment ends. Managing these impacts is a key part of ...

"I've always had very small breasts. Now I'm 4 months along and my breasts have yet to grow. Is this normal? I keep reading about how my breasts should be huge by now. Will they ever grow? And if they ...

Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line ...

Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in invasive ...